Evidence map›Paper›PMID 34998722›Full record

ArticleJournal of geriatric oncology2022

Association of circulating leukocyte telomere length with survival in patients with colorectal cancer.

Svenja Pauleck, Biljana Gigic, Richard M Cawthon, Jennifer Ose, Anita R Peoples, Christy A Warby, Jennifer A Sinnott, Tengda Lin, Juergen Boehm, Petra Schrotz-King and 10 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of geriatric oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 2 countries.

Svenja PauleckHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; University of Leipzig Medical Center, Medical Faculty, Leipzig, Germany.
Biljana GigicHeidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Richard M CawthonDepartment of Human Genetics, University of Utah, Salt Lake City, UT, USA.
Jennifer OseHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
Anita R PeoplesHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
Christy A WarbyHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
Jennifer A SinnottHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA; Department of Pediatrics, University of Utah, Salt Lake City, UT, USA; Department of Statistics, The Ohio State University, Columbus, OH, USA.
Tengda LinHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
Juergen BoehmHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Petra Schrotz-KingNational Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Christopher I LiFred Hutchinson Cancer Research Center, Seattle, WA, USA.
David ShibataUniversity of Tennessee Health Science Center, Memphis, TN, USA.
Erin M SiegelH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Jane C FigueiredoCedars-Sinai Medical Center, Los Angeles, CA, USA.
Adetunji T ToriolaDepartment of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO, USA.
Martin SchneiderHeidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Alexis B UlrichHeidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Albrecht HoffmeisterMedical Department II, Division of Gastroenterology, University of Leipzig Medical Center, Leipzig, Germany.
Cornelia M UlrichHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
Sheetal HardikarHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: sheetal.hardikar@hci.utah.edu.
Cedars-Sinai Medical Center · USFred Hutch Cancer Center · USGerman Cancer Research Center · DEHuntsman Cancer Institute · USLeipzig University · DEMoffitt Cancer Center · USUniversity of Tennessee Health Science Center · USUniversity of Utah · USWashington University in St. Louis · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Novel Biomarkers for Cancer-Related Fatigue: Integrating Metabolomics, Genomics and BehaviorsR01NR018762 · NINR · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., JIM, HEATHER S.L. · 2020 to 2024
$3.4M
Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal NeoplasiaK07CA222060 · NCI · UNIVERSITY OF UTAH · PI HARDIKAR, SHEETAL · 2018 to 2022
$791k
NCI NIH HHS K07 CA222060NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS U01 CA206110NINR NIH HHS R01 NR018762
6 · The paper itself

Abstract

introductionTelomere shortening, as seen with aging, can cause chromosomal instability and promote cancer progression. We investigated the association between circulating telomere length and overall and disease-free survival in a sub-cohort of patients with colorectal cancer.

methodsBaseline genomic DNA from blood leukocytes was extracted from N = 92 newly diagnosed stage I-IV patients with colorectal cancer enrolled at the ColoCare Study site in Heidelberg, Germany. Detailed information on clinicodemographic (including age) and lifestyle risk factors, and clinical outcomes (including recurrence and survival) was collected. Telomere length was measured in DNA using multiplex quantitative polymerase chain reaction. Kaplan Meier survival curves were generated comparing shorter to longer telomere lengths with log-rank testing.

resultsThe mean T/S ratio for study patients was 0.5 (range: 0.3-0.9). Shorter telomeres were associated with older age at baseline. Patients with shorter telomeres experienced a worse overall and disease-free survival, although this association did not reach statistical significance. Kaplan-Meier survival curves for those with circulating telomere length below vs. above the median showed poorer overall (log-rank p = 0.31) and disease-free survival (long-rank p = 0.23).

conclusionsOur results suggest that individuals with shorter telomeres, as seen with aging, may experience a worse overall and disease-free survival after colorectal cancer diagnosis. Larger sample sizes with longer follow-up are needed to further evaluate telomere length as a prognostic biomarker in colorectal cancer progression.

Indexed as

Colorectal NeoplasmsTelomereDisease-Free SurvivalHumansKaplan-Meier EstimateLeukocytesColorectal cancerDisease-free survivalLeukocyte telomere lengthOverall survival

Identifiers

PMID34998722
PMCPMC9197691
OpenAlexW4206404433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.